The efficacy and safety of sodium tanshinone ⅡA sulfonate injection in the treatment of unstable angina pectoris: A systematic review and meta-analysis.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
07
04
2023
accepted:
16
08
2023
medline:
4
9
2023
pubmed:
31
8
2023
entrez:
31
8
2023
Statut:
epublish
Résumé
To systematically evaluate the efficacy and safety of Sodium tanshinone ⅡA sulfonate injection (STS) in the treatment of unstable angina pectoris (UAP). CNKI, Wanfang, VIP, CBM, PubMed, Cochrane Library, Web of Science, Embase were searched by computer. The research covers the clinical randomized controlled trials of STS in the treatment of unstable angina pectoris published from the establishment of the library to January 31, 2023. Two researchers independently screened the literature, extracted data and evaluated the risk of research bias, and then conducted meta-analysis with RevMan5.3 software. A total of 37 randomized controlled trials were included, involving 3926 patients in total. Meta analysis results showed that, compared with conventional western medicine alone, STS combined with conventional western medicine could reduce the frequency (SMD = -2.61, 95%CI[-4.27, -0.96], P = 0.002) and duration (SMD = -4.01, 95%CI[-6.18, -1.84], P = 0.0003) of angina pectoris, improve ECG efficacy (OR = 3.61, 95%CI[2.79, 4.68], P<0.00001) and clinical symptom efficacy (OR = 4.02, 95%CI[3.32, 4.87], P<0.00001), reduce TG(SMD = -0.60, 95%CI[-1.04, -0.16], P = 0.008), TC(SMD = -3.86, 95%CI[-6.37, -1.34], P = 0.003), and LDL-C(SMD = -1.54, 95%CI[-2.67, -0.42], P = 0.007), decrease plasma viscosity(SMD = -1.02, 95%CI[-1.58, -0.47], P<0.0003), whole blood low shear viscosity(SMD = -0.85, 95%CI[-1.21, -0.49], P<0.00001), whole blood high shear viscosity(SMD = -0.82, 95%CI[-1.44, -0.20], P = 0.009), and erythrocyte aggregation index(SMD = -1.00, 95%CI[-1.75, -0.25], P = 0.009), and bring down CRP(SMD = -1.39, 95%CI[-1.91, -0.86], P<0.00001). The incidence of adverse reactions in the treatment group was higher than that in the control group (OR = 2.26, 95%CI[1.06, 4.85], P = 0.04). Neither of the two groups suffered from abnormal liver and kidney function during the study process. STS combined with routine treatment has a definite clinical efficacy and certain safety in the treatment of UAP, but it needs to be further confirmed by high-quality and low-bias randomized controlled trials in the future.
Identifiants
pubmed: 37651454
doi: 10.1371/journal.pone.0290841
pii: PONE-D-23-09981
pmc: PMC10470971
doi:
Substances chimiques
tanshinone II A sodium sulfonate
69659-80-9
Phenanthrenes
0
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0290841Informations de copyright
Copyright: © 2023 Wu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Thorac Dis. 2014 Dec;6(12):1794-9
pubmed: 25589975
J Tradit Chin Med. 2016 Apr;36(2):144-50
pubmed: 27400467
BMJ. 2021 Mar 29;372:n160
pubmed: 33781993
Chin J Integr Med. 2017 Apr;23(4):306-311
pubmed: 27921196
Biomed Pharmacother. 2019 Oct;118:109362
pubmed: 31545252
Am J Emerg Med. 2017 Mar;35(3):502-507
pubmed: 28089498
Chin J Integr Med. 2018 Feb;24(2):156-160
pubmed: 29181731
Phytother Res. 2017 Aug;31(8):1162-1172
pubmed: 28634988
Medicine (Baltimore). 2016 Dec;95(51):e5692
pubmed: 28002341
N Engl J Med. 2000 Jan 13;342(2):101-14
pubmed: 10631280
Front Pharmacol. 2019 Dec 24;10:1542
pubmed: 31920681